Dale Greiner to Immunosuppressive Agents
This is a "connection" page, showing publications Dale Greiner has written about Immunosuppressive Agents.
Connection Strength
0.550
-
Miller DM, Thornley T, Pearson T, Yamazaki M, Brehm MA, Rossini AA, Greiner DL. TLR agonists abrogate co-stimulation blockade-induced mixed chimerism and transplantation tolerance. Ann N Y Acad Sci. 2008 Dec; 1150:149-51.
Score: 0.273
-
King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009 Jul; 157(1):104-18.
Score: 0.071
-
Seung E, Mordes JP, Greiner DL, Rossini AA. Induction of tolerance for islet transplantation for type 1 diabetes. Curr Diab Rep. 2003 Aug; 3(4):329-35.
Score: 0.047
-
Waegell W, Babineau M, Hart M, Dixon K, McRae B, Wallace C, Leach M, Ratnofsky S, Belanger A, Hirst G, Rossini A, Appel M, Mordes J, Greiner D, Banerjee S. A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection. Transplant Proc. 2002 Aug; 34(5):1411-7.
Score: 0.044
-
Bortell R, Moss J, McKenna RC, Rigby MR, Niedzwiecki D, Stevens LA, Patton WA, Mordes JP, Greiner DL, Rossini AA. Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. J Immunol. 2001 Aug 15; 167(4):2049-59.
Score: 0.041
-
Dai C, Walker JT, Shostak A, Padgett A, Spears E, Wisniewski S, Poffenberger G, Aramandla R, Dean ED, Prasad N, Levy SE, Greiner DL, Shultz LD, Bottino R, Powers AC. Tacrolimus- and sirolimus-induced human ? cell dysfunction is reversible and preventable. JCI Insight. 2020 01 16; 5(1).
Score: 0.037
-
Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000 Jan 01; 164(1):512-21.
Score: 0.037